Which peptides are studied in relation to GrimAge?
GrimAge is a DNA methylation-based epigenetic clock. This page summarises the peptide and peptide-adjacent research that has been conducted in relation to it, and states plainly where the evidence is animal-only or in vi
GrimAge is a second-generation DNA methylation-based epigenetic clock, developed as a composite biomarker that incorporates methylation surrogates for plasma proteins alongside chronological age and smoking pack-years. It is one of several epigenetic clocks used to estimate biological age and to calculate epigenetic age acceleration (EAA) — the difference between a sample's estimated biological age and the individual's chronological age [1]. GrimAge is measured from DNA extracted from blood or saliva, and it is distinct from first-generation clocks such as Horvath and Hannum in that it was trained against morbidity and mortality outcomes rather than chronological age alone.
GrimAge is not a peptide, and no peptide is a component of the GrimAge algorithm. The research literature that connects peptides to GrimAge is therefore indirect: it consists of studies in which a peptide, peptide hormone, or peptide-containing biological preparation was administered or measured, and GrimAge or a related epigenetic clock was used as an outcome or covariate. The pathway most consistently implicated across this work is the somatotropic axis — growth hormone (GH), insulin-like growth factor 1 (IGF-1), and their downstream signalling — together with the inflammatory and renal markers that GrimAge uses as methylation surrogates.
Research Studies
GrimAge and the somatotropic axis in human cohort studies
Because GrimAge includes methylation-based surrogates for proteins such as cystatin C and growth differentiation factor 15 (GDF15), studies examining GH/IGF-1 signalling and epigenetic aging have used GrimAge as one of several clock outcomes. These are observational human studies; they measure endogenous hormone levels rather than administering peptides, and they report associations rather than causal effects. The direction and magnitude of the association between IGF-1 and GrimAge acceleration have varied between cohorts, and no consensus value can be stated from the evidence available here.
Epigenetic age acceleration and genetic susceptibility in Asian populations
A genome-wide association study of epigenetic age acceleration was conducted in a Korean population using multiple epigenetic clocks, including GrimAge, to examine ethnic differences and individual variability in EAA [3]. The study identified Asian-specific genetic susceptibility loci for epigenetic age acceleration. This is a genetic epidemiology study; it does not involve peptide administration, and it is reported here as background on how GrimAge behaves as a measured outcome across populations.
Seasonality and biological age measurement in adults
A registered study is evaluating the effect of seasonal variation on biological age in adults, with the stated aim of improving the design and analysis of long-term lifestyle interventions targeting biological clocks [1]. Biological age in that work is assessed from blood or saliva samples, and the study frames age acceleration as the difference between chronological and biological age. This is a measurement and methodology study; it does not test a peptide, and it is relevant to GrimAge research only insofar as it addresses the stability of clock readouts over time.
Autologous bone marrow aspirate and epigenetic outcomes in Parkinson's disease
A pilot study evaluated the safety, tolerability, and exploratory epigenetic outcomes of a single same-day autologous bone marrow procedure in ten adults with Parkinson's disease or Parkinson-plus syndromes [2]. Participants underwent posterior superior iliac spine bone marrow aspiration under local anaesthesia. The unprocessed aspirate was filtered and given intravenously in normal saline on the same day, while a portion was centrifuged to produce bone marrow aspirate concentrate, which was delivered intranasally by mucosal atomisation. Cells were not expanded in culture and were not genetically modified. The population was adults with PD or PPS, the design was a pilot safety study, and the epigenetic outcomes were exploratory. Bone marrow aspirate is a heterogeneous cell and protein preparation, not a defined peptide, and the study is reported here because it is one of the few interventional human protocols in which epigenetic endpoints were collected alongside a biological preparation.
GDF15 as a GrimAge component and a peptide-measurable analyte
GDF15 is a secreted protein whose methylation surrogate is embedded in the GrimAge composite. It is measured in human plasma by immunoassay, and it is one of the analytes that links GrimAge to inflammatory and metabolic signalling. Studies that report GDF15 alongside GrimAge are measuring an endogenous protein, not administering one. No interventional human study in the evidence available here reports administering GDF15 or a GDF15-derived peptide with GrimAge as an endpoint.
Comparison of clock types used in peptide-related research
| Clock | Training target | Typical tissue | Peptide relevance in the evidence |
|---|---|---|---|
| GrimAge | Morbidity and mortality; plasma protein surrogates | Blood, saliva | Includes methylation surrogates for secreted proteins such as GDF15 |
| First-generation clocks (e.g. Horvath, Hannum) | Chronological age | Multiple tissues | Used as comparator outcomes in multi-clock EAA studies [3] |
| Biological age from blood or saliva panels | Composite biological age | Blood, saliva | Used in seasonality and lifestyle-intervention methodology work [1] |
Where the evidence is animal-only or in vitro
For the specific question of peptides and GrimAge, the human evidence available here is limited to observational cohort work, genetic epidemiology, and one pilot safety study of a bone marrow preparation [2]. Mechanistic work on GH/IGF-1 signalling and methylation is largely conducted in cell culture and animal models, and those findings cannot be transferred to human GrimAge outcomes. Any statement that a given peptide changes GrimAge in humans would require an interventional human trial with GrimAge as a pre-specified endpoint; no such trial appears in the evidence provided.
What the evidence does not establish
- No peptide has been shown in the evidence provided here to lower GrimAge in humans.
- No dose, route, or schedule for any peptide can be derived from these sources.
- GrimAge is a statistical composite, not a receptor or a target that a peptide can bind.
- Associations between endogenous hormone levels and clock acceleration are not evidence of an intervention effect.
If you are reading this for personal health reasons
The materials described on this page are sold for laboratory research use only, and nothing here is medical advice. We do not provide dosing, administration, or clinical guidance for any compound. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Evaluation of the Effect of Seasonality on Biological Age in Adults — https://clinicaltrials.gov/study/NCT07242833
- [2] Autologous Bone Marrow Aspirate (IV) and Bone Marrow Concentrate (Intranasal) for Parkinson's Disease and Parkinson-Plus Syndromes (SPARC-PD) — https://clinicaltrials.gov/study/NCT07751640
- [3] A genome-wide association study identifies Asian-specific genetic susceptibility for epigenetic age acceleration — https://europepmc.org/article/PMC/PMC13356206